With more than half of 2015 behind us it is clear that this is the year of wearables. When Fitbit, Inc. hit Wall Street in June it was the third largest U.S. IPO of the year according to Dealogic. While this fitness-tracking wearable developer is now valued at around $4.1 billion and poised for growth, what does this say about the future of wearables in the healthcare market? What does the long-term viability look like for this market?
Pew Research Center indicates that 87 percent of Americans are using the Internet regularly. With social and digital media becoming ever-more prevalent, it makes sense that within the clinical trial industry, researchers are now looking to it as a way to control some of the escalating R&D costs and make the process more patient-centric.
Hyper-local advertising is poised to transform how clinical trial marketers connect with patients. By providing a cost-effective platform to engage their audiences by matching ads in context of consumers’ physical location, hyper-local targeting delivers relevant messages to the right person at precisely the right time and place – and can cost as little as one-fifth of search engine marketing.
According to TheDataLab, the use of mobile apps in clinical trials has shown to increase patient adherence and completion rates from just over 50% to over 80%. This and other figures are pointing to a shift in how data-driven mobile app development is drastically transforming how diseases are being treated – both inside and outside of the clinical trial setting. Why is data-driven methodology in mobile app development transforming healthcare and disease management?
We all know that social media has the power to reach the masses in record speed. According to Quorum Review IRB, which recently led a webinar on embracing social media for clinical trials, there are more than one billion users on Facebook and 500 million users on Twitter. Within clinical research, social media can be an easy way to connect with the patient population. It offers the chance to get personal with like-minded people who are open and willing to share their journey regarding a specific diagnosis or indication.
In June of 2014, Japan’s prime minister, Shinzo Abe said he wanted to increase the market for robots in Japan to $22 billion by 2020 and launched a “robot revolution realization council” to create a five-year blueprint to push the industry forward. On the heels of this announcement the New Energy and Industrial Technology Development Organization (NEDO) has recruited Kawasaki and Panasonic to create a robot to perform more intricate tasks, including brain surgery. Their goal is to have products in clinical trials as soon as 2019. This increase in robotic advancement is expected to minimize error and maximize efficiency and precision during medical procedures. In addition, the use of robots to complete jobs usually done by humans has the potential to decrease overall costs in the coming years.
As we discussed in part I of our blog series on adaptive patient recruitment, the rare disease community is constantly striving to invest in developing new treatments. While there is a huge unmet need in this area, there are recruitment tactics that effectively provide support. Beyond the introduction of an early support program, which Jaime Cohen discussed in our previous post, there are additional strategies that can assist in higher recruitment numbers for rare disease. In part II of our series on rare disease we explore further.
With another successful DIA Annual Meeting behind us, as well as some time to reflect, we wanted to thank our industry partners and colleagues for making this year’s meeting one of the best yet. We also want to highlight some of the thought-provoking work and innovations that raised the already high bar. Here goes.
Topics: Patient Centricity
The average person spends nearly 4.4 hours of leisure time in front of screens each day. People are online, on their phones or using their tablets in increasing amounts. Given this statistic, it seems natural for there to be a shift from native advertising to content marketing. It’s best to reach consumers where they already are and to push relevant content to them directly to pique interest.
We know that social media usage is up year-over-year across all ages, but how is it being put to use for clinical research? On June 11th I had the pleasure of participating in a social media forum hosted by MassBio with PatientsLikeMe, Biogen and Boston Children’s Hospital. It was an eye opening discussion that looked at the use of social media within clinical trials from the varying perspectives of advocacy groups, IRBs and pharmaceutical companies, each with different goals in mind and facing their own set of unique challenges.